Dracen Pharmaceuticals Report issue

For profit Phase 2
Founded: Baltimore MD United States (2016)

Organization Overview

First Clinical Trial
2020
NCT04471415
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

Dracen Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 2 Trials (3)

atezolizumab (Tecentriq) (1 trial)

durvalumab (imfinzi) (1 trial)

Sirpiglenastat (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Lung Neoplasms (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3